Feb 23 2024 41 mins 3
After decades of lagging nearly many other disease areas, neurology is finally seeing signs of significant innovation.
One of the biggest reasons it’s trailed behind has been the difficulty in teasing out complex neurobiology – an understanding necessary to design novel medicines. Rapport Therapeutics is playing a significant role in turning the tide.
Rapport creates precision neuromedicines that act only in the brain regions where disease originates, avoiding the side effects that affect many of today’s treatments.
This week, we have a conversation with Rapport CEO Abe Ceesay, about the company’s transformational approach, and about what’s new in neuromedicine.
00:45-02:43: About Rapport
02:43-05:01: What attracted you to Rapport?
05:01-09:13: What are the issues in developing drugs in neuroscience?
09:13-12:09: What are the areas with unmet needs?
12:09-16:24: What are receptor-associated proteins?
16:24-19:25: How do you avoid side-effects?
19:25-20:35: Are other companies working in this space?
20:35-23:49: How do you approach designing treatments for different conditions?
23:49-26:10: Where is Rapport currently with clinical trials?
26:10-28:26: How do you define success in your trials?
28:26-30:27: Is your treatment used in conjunction with others?
30:27-32:45: How is your treatment administered?
32:45-36:10: Why is there increased interest in developing drugs for neurological disorders?
36:10-38:20: Looking to the future
38:20-40:44: What are the next steps for Rapport?
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
